I hereby certify that this correspondence is being deposited with the United

States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 015280-271100US Client Reference No.: ERECEIVED

TECH CENTER 1600/2900

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

DECEMBER 10,2

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 1 5 2003

In re application of:

Gonzalez, Frank J. et al.

Application No.: 09/308,080

Filed: October 28, 1999

For: METHODS AND COMPOSITIONS

FOR DETECTING

DIHYDROPYRIMIDINE

DEHYDROGENASE SPLICING

MUTATIONS

Examiner: Ramirez, Delia M.

Art Unit: 1652

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Gonzalez, Frank J. et al. Application No.: 09/308,080

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Frank J. Mycroft Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 925-472-5000

Fax: 925-472-8895

FJM:mrv

60097522 v1

THA ENGOSTITUTE FOR 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

Complete if Known			
Application Number	09/308,080		
Filing Date	October 28, 1999		
First Named Inventor	Gonzales, Ph.D., Frank		
Art Unit	1652		
Examiner Name	Ramirez, Delia M.		
Attorney Docket Number	015280-271100US		

	U.S. PATENT DOCUMENTS+					
/		Document Number				
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			_		,	

	FOREIGN PATENT DOCUMENTS							
5	0.11	Foreign Patent Document				Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No. ¹	Country Code ³	Number⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	1	wo	95/28489		10-26-1995	The UAB Research Foundation		
					_			
			,					
. ,								

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional).

*Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04.

*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

*Strind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

*Applicant's unique citation if not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

*Applicant's unique citation designation number (optional).

**Province Translation is conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

**Province Translation is conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Draw line through citation is not in conformance with MPEP 609. Draw line through citation is not include through citation in conformance with MPEP 609. Draw line through citation in conformance with MPEP 609. Draw line through citation in conformance with MPEP 609. Draw line through citation in conformance with MPEP 609. Draw line through citation in conformance with MPEP 609. Draw line through citation in conformance with MPEP 609. Draw line through citation in conformance with MPEP 609. Draw line through citation in conformance place a check mark here if English language Translation is attached. 60097522 v1

Substitute for form 1449B/PTO

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 09/308,080 Application Number October 28, 1999 Filing Date First Named Inventor Gonzales, Ph.D., Frank Art Unit 1652 Examiner Name Ramirez, Delia M.

(use as many sheets as necessary)

015280-271100US Sheet of Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS					
Examiner initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2		
	2	KUILENBURG, Andre B.P. et al.: "Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD Deficiency"; Clinical Cancer Research, Vol. 7; pp. 1149-1153; May 2001			
	3	KUIVANIEMI, Helena et al.: "Identical G+1 to A mutations in three different introns of the Type III procollagene gene (COL3A1) produce different patterns of RNA splicing in three variants ot Ehlers-Danlos Syndrome IV"; J. Biological Chemistry, Vol. 265, No. 20; pp. 12067-12074; July 15, 1990	1		
	4	YOKOTA, Hiroshi et al.: "cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, and enzyme associated with 5-flouorouracil toxicity and congenital thymine uracilura"; J. Biological Chemistry, Vol. 269, No. 37; pp. 23192-23196; September 16, 1994			
	5	OMIM Entry for "Dyhydropyrimidine Dehydrogenase; DPYD" printed on December 3, 2003; http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=274270 ; 10 pages			

Examiner	 Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.